Efficacy and safety of glycemic control in type 2 diabetes patients when switched to mitiglinide/voglibose fixed-dose combination therapy.
Phase 4
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000007619
- Lead Sponsor
- Keio University School of Medicine Department of Nephrology, Endocrinology and Metabolism
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1)Contraindicated for mitiglinide or voglibose. 2)Patients who received glinide or alpha GI more than daily dose*. (Daily dose: mitiglinide 10mg/time, nateglinide 90mg/time, voglibose 0.3mg/time, acarbose 100mg/time, miglitol 50mg/time) 3)Patients who had been previously receiving DPP4 inhibitor or GLP-1 analogue, insulin. 4)Anticipated to be non-compliant to the trial by principal investigators opinion.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method %MPR, HbA1c
- Secondary Outcome Measures
Name Time Method 1,5-AG, glycoalbumin, serum lipid profile, blood pressure, body weight, hypoglycemia, liver function, DTSQ